

# The impact of moderate wine consumption on the risk of developing prostate cancer

Mihai Dorin Vartolomei,<sup>1,2,\*</sup>  
 Shoji Kimura,<sup>2,3,\*</sup>  
 Matteo Ferro,<sup>4</sup>  
 Beat Foerster,<sup>2,5</sup>  
 Mohammad Abufaraj,<sup>2,6</sup>  
 Alberto Briganti,<sup>7</sup>  
 Pierre I Karakiewicz,<sup>8</sup>  
 Shahrokh F Shariat<sup>2,9,10,11</sup>

<sup>1</sup>Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania;

<sup>2</sup>Department of Urology, Medical University of Vienna, Vienna, Austria;

<sup>3</sup>Department of Urology, Jikei University School of Medicine, Tokyo, Japan;

<sup>4</sup>Division of Urology, European Institute of Oncology, Milan, Italy; <sup>5</sup>Department of Urology, Kantonsspital Winterthur, Winterthur, Switzerland; <sup>6</sup>Division of Urology, Department of Special Surgery, Jordan University Hospital, The University of Jordan, Amman, Jordan; <sup>7</sup>Department of Urology, Vita Salute San Raffaele University, Milan, Italy; <sup>8</sup>Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Centre, Montreal, Canada; <sup>9</sup>Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; <sup>10</sup>Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA; <sup>11</sup>Department of Urology, Weill Cornell Medical College, New York, NY, USA

<sup>1</sup>Department of Cell and Molecular Biology, University of Medicine and Pharmacy, Tirgu Mures, Romania;

\*These authors contributed equally to this work

Correspondence: Shahrokh F Shariat  
 Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna General Hospital, Währinger Gürtel 18-20, A-1090 Vienna, Austria  
 Tel +43 1 40400 26150  
 Fax +43 1 40400 23320  
 Email: shahrokh.shariat@meduniwien.ac.at

**Objective:** To investigate the impact of moderate wine consumption on the risk of prostate cancer (PCa). We focused on the differential effect of moderate consumption of red versus white wine.

**Design:** This study was a meta-analysis that includes data from case-control and cohort studies.

**Materials and methods:** A systematic search of Web of Science, Medline/PubMed, and Cochrane library was performed on December 1, 2017. Studies were deemed eligible if they assessed the risk of PCa due to red, white, or any wine using multivariable logistic regression analysis. We performed a formal meta-analysis for the risk of PCa according to moderate wine and wine type consumption (white or red). Heterogeneity between studies was assessed using Cochrane's Q test and *I*<sup>2</sup> statistics. Publication bias was assessed using Egger's regression test.

**Results:** A total of 930 abstracts and titles were initially identified. After removal of duplicates, reviews, and conference abstracts, 83 full-text original articles were screened. Seventeen studies (611,169 subjects) were included for final evaluation and fulfilled the inclusion criteria. In the case of moderate wine consumption: the pooled risk ratio (RR) for the risk of PCa was 0.98 (95% CI 0.92–1.05, *p*=0.57) in the multivariable analysis. Moderate white wine consumption increased the risk of PCa with a pooled RR of 1.26 (95% CI 1.10–1.43, *p*=0.001) in the multivariable analysis. Meanwhile, moderate red wine consumption had a protective role reducing the risk by 12% (RR 0.88, 95% CI 0.78–0.999, *p*=0.047) in the multivariable analysis that comprised 222,447 subjects.

**Conclusions:** In this meta-analysis, moderate wine consumption did not impact the risk of PCa. Interestingly, regarding the type of wine, moderate consumption of white wine increased the risk of PCa, whereas moderate consumption of red wine had a protective effect. Further analyses are needed to assess the differential molecular effect of white and red wine conferring their impact on PCa risk.

**Keywords:** wine, prostate cancer, alcohol, risk of cancer, meta-analysis

## Introduction

Prostate cancer (PCa) is the most commonly diagnosed cancer among men in the USA with an estimated 161,360 new cases in 2017.<sup>1</sup> Worldwide, it is the second most common cancer and the sixth cause of cancer death among men,<sup>2</sup> with an estimated 1.1 million cases and 307,000 deaths in 2012.<sup>3</sup> There are well-established risk factors for PCa, such as family history,<sup>4,5</sup> hereditary genes,<sup>6</sup> racial/ethnic background (eg, African ethnicity),<sup>7</sup> and age. Also, a wide variety of exogenous/environmental/lifestyle factors have been shown to impact the risk of PCa development and progression.<sup>8</sup> For example, alcohol intake has been recently suggested as a risk factor for PCa

development in a meta-analysis that included 27 studies showing a significant dose–response relationship between the level of alcohol intake and the risk of PCa.<sup>9</sup> On the other hand, a large prospective European cohort study failed to observe an association between alcohol consumption and PCa risk.<sup>10</sup> Both studies did not assess the type of alcohol consumption. Despite association between alcohol intake and PCa risk, the effect of wine consumption on PCa risk is not yet fully understood. Furthermore, association between wine consumption and risk of PCa demands further investigation as several studies have suggested that polyphenols from red wine have a chemoprotective role in PCa cell lines.<sup>11,12</sup>

Therefore, we hypothesized that wine, specifically red wine, has a protective effect on PCa development. To test this hypothesis, we performed a meta-analysis assessing the effect of moderate wine consumption on PCa in a first step and then that of red and white wine differentially.

## Materials and methods

A systematic search of Web of Science, Medline/PubMed, and Cochrane library was performed using the terms “wine” and “prostate cancer” on December 1, 2017. All original articles that fulfilled the inclusion criteria were included. We performed additional cross-checking of reference lists, including those of previous meta-analyses and “hand-searched” for additional references in the selected articles, reviews, and meta-analyses reporting on the topic.

Informed consent was not required for this type of study.

## Inclusion and exclusion criteria

The PICOS (Population, Intervention, Comparator, Outcome and Study design) approach was utilized to define study eligibility according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) criteria ([www.prisma-statement.org](http://www.prisma-statement.org)).<sup>13</sup> Studies were considered eligible if they assessed the risk of PCa due to red and white wine and wine in general using multivariable logistic regression analysis in the general population or compared with a control group of individuals without PCa. For each selected study, the following items were recorded: first author’s name, year of publication, country, number of patients, age, and variables used in the multivariable analysis, risk ratios (RRs) of PCa in multivariable analysis, dose of wine and follow-up in case of cohort studies. Two independent investigators (MDV and SK) assessed study quality using the Newcastle-Ottawa Scale (NOS)<sup>14</sup> for cohort studies. A total score of 5 or less was considered low; 6–7 was considered intermediate, and 8–9 was considered high quality. Most included studies

had intermediate and high quality score according to NOS (Figure S1).

## Statistical analysis


We performed a formal meta-analysis for the risk of PCa according to moderate wine consumption and moderate consumption of type of wine (white or red). RRs with their 95% CIs from each study were used to calculate pooled RRs. Pooled estimates were calculated with the fixed effect model, if no significant heterogeneity was identified; alternatively, the random effect model was used when significant heterogeneity was detected. Statistical heterogeneity was defined based on Cochrane’s  $Q$   $p$ -value or  $I^2$  statistics. We performed “leave-one-out” sensitivity analysis. To evaluate publication bias, Egger linear regression and funnel plots were examined. In case of reporting only RRs for low- and high-risk PCa, we included in the meta-analysis the RRs for high-risk PCa. Statistical analyses were performed using Stata 11.0 statistical software (Stata Corp., College Station, TX, USA).

## Results


A total of 930 abstracts and titles were initially identified. After removal of duplicates, reviews, and conference abstracts, 83 full-text original articles were screened. Finally, 17 studies (a total of 611,169 subjects) were included for final evaluation fulfilling the inclusion criteria.<sup>15–31</sup> The PRISMA flow chart summarizing the process of study selection is shown in Figure 1. Potential publication bias was examined by both a funnel plot and an Egger’s test and we did not find any publication bias (Figure 2). Assessment of the main studies biases are shown in the risk bias table (Figure S2).

## Effect of moderate consumption of wine on PCa risk

Overall, 14 studies (455,413 subjects) fulfilled the inclusion criteria regarding moderate wine consumption and risk of PCa (6 cohort and 8 case–control studies).<sup>15–22,24,26,27,29–31</sup> The main characteristics of the studies, as well as dose of wine consumption, are shown in Table 1. In the first meta-analysis, we included all the studies regardless of design. The pooled RR for the risk of PCa was 0.98 (95% CI 0.92–1.05,  $p=0.57$ ) in the multivariable analysis (Figure 3). The Cochrane’s  $Q$  test ( $\chi^2=17.6$ ;  $p=0.19$ ) and  $I^2$  test ( $I^2=23.8\%$ ) did not show a significant heterogeneity. The funnel plots identified one study over the pseudo 95% CI (Figure 2A). Furthermore, we performed a second meta-analysis in which we included only cohort studies (438,302 subjects from which



**Figure 1** PRISMA flow chart of the study selection process.  
**Abbreviation:** PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analysis.



**Figure 2** Funnel plots with pseudo 95% confidence limits for the association between moderate wine intake and the risk of PCa in all the included studies **(A)**, only in cohort-studies **(B)**, association between moderate white wine intake and the risk of PCa **(C)**, and association between moderate red wine intake and the risk of PCa **(D)**.  
**Abbreviations:** PCa, prostate cancer; SE, standard error; HR, hazard ratio.

**Table 1** Studies investigating the impact of wine consumption on the risk of PCa

No.	Study	Year	Country	Study type	No. of pts	Age (years)	Variables	RRs wine and risk of PCa	Dose	Follow-up (years)
1	Jain et al <sup>15</sup>	1998	Canada	Case-control	637/ 617 PCa	69.8	Age, smoking status, total energy intakes, and consumption of other types of alcohol	0.77 (0.60–0.99)	0–9 g/day	–
2	Schuurman et al <sup>16</sup>	1999	the Netherlands	Case-cohort	58,279/ 680 PCa	55–69	Age, socioeconomic status, and family history of PCa	1.1 (0.8–1.4)	0.1–4 g/day	6.3
3	Sesso et al <sup>17</sup>	2001	USA	Case-cohort	7,612/ 366 PCa	66.6	Age, BMI, physical activity, smoking status, and family history of PCa	1.05 (0.49–2.27)	≥3 drinks/day	6
4	Albertsen and Grønbaek <sup>18</sup>	2002	Denmark	Case-cohort	12,989/ 233	NA	Age, education, physical activity, BMI, smoking status, and study of origin	1.15 (0.85–1.56)	1–13 drinks/week	12.3
5	Crispo et al <sup>19</sup>	2004	Italy	Case-control	1,451/ 1,294 PCa	45–75	Age, center, education, BMI, physical activity, and family history of PCa	0.95 (0.64–1.39)	3–4 drinks/day	–
6	Platz et al <sup>20</sup>	2004	USA	Case-cohort	47,843/ 2,479 PCa	40–75	Age, BMI at age 21 years, height, pack-years of smoking in the previous decade, family history of PCa, major ancestry, diabetes, vasectomy, vigorous physical activity, and intakes of total energy, calcium, fructose, tomato sauce, red meat, fish, vitamin E (> 15 mg/day), and α-linolenic acid	1.10 (0.96–1.25)	2–5.9 g/day	12
7	Chang et al <sup>21</sup>	2005	Sweden	Case-control	1,130/ 1,499 PCa	45–79	Age, smoking history, BMI, family history of PCa, intake of other alcohol types, dairy products, red meat, and fruits and vegetables	1.0 (0.8–1.3)	0–15 g/day	–
8	Schoonen et al <sup>22</sup>	2005	King County, WA, USA	Case-control	703/ 753 PCa	40–64	Age, PSA screening, total lifetime number of female sexual partners, smoking status, and consumption of other types of alcohol	1.22 (0.71–2.11)	≥8 drinks/week	–
9	Baglietto et al <sup>24</sup>	2006	Melbourne, Australia	Case-cohort	16,872/ 732 PCa	27–75	Age, education, BMI, smoking, total energy intake, and previous medical conditions	0.97 (0.81–1.17) 1.02 (0.83–1.26)	1–19g/day	>10
10	Benedetti et al <sup>26</sup>	2009	Canada	Case-control	507/ 374 PCa	Mean 59.7/ 62.9 PCa	Age, smoking status, cigarette-year, respondent status, ethnicity, census tract income, years of schooling, and time since quitting	Low-grade PCa 0.76 (0.51–1.14) High-grade PCa 0.93 (0.59, 1.45)	>7 drinks/week	–

11	Watters et al <sup>27</sup>	2010	11 States from USA	Case-cohort	294,707/ 17,227 PCa	50–71	Age, race, education, marital status, height, BMI, physical activity, family history of PCa, diabetes, self-reported health status, cigarette smoking, prostate-specific antigen screening and digital rectal examination, total energy excluding alcohol, a-tocopherol, calcium, red meat, fish, tomato, a-linolenic acid, and selenium	1.05 (1–1.09) Low-grade PCa 0.99 (0.79–1.23) High-grade PCa	<1 drink/day	>8
12	McGregor et al <sup>29</sup>	2013	Alberta, Canada	Case-control	1,039/ 947 PCa	Mean 68.5/69.8	Age, residence region, education, family history of PCa, BPH, number of DRE tests, number of PSA tests	0.8 (0.6–1)	1–7 drinks/week	–
13	Demoury et al <sup>30</sup>	2016	Montreal, Canada	Case-control	≥Stage II 1,994/ 1,933 PCa	Mean 65/64	Age, ancestry, family history of PCa, education, smoking, physical activity, BMI, fruit and vegetables consumption, history of diabetes, and other types of beverages	1.12 (0.88–1.43) Low-grade PCa 0.99 (0.72–1.37) High-grade PCa	>35 drinks/year	–
14	Papa et al <sup>31</sup>	2017	Victoria, Australia	Case-control	951/ 1,282 agg. PCa	Median 62.9/66.8	Age, family history of PCa, smoking status, BMI, socioeconomic status, ethnicity and country of birth, and intakes of the other beverage types	0.64 (0.45–0.91)	5–7 days/week	–


**Abbreviations:** PCa, prostate cancer; BMI, body mass index; PSA, prostate-specific antigen; BPH, benign prostatic hyperplasia; DRE, digital rectal examination; agg, aggressive (high-grade or advanced disease); pts, patients; RRs, risk ratios.

19,238 developed PCa during observation/follow-up). The results were confirmed with a pooled RR of 1.06 (95% CI 0.96–1.15,  $p=0.22$ ) in the multivariable analysis (Figure 4). The Cochrane's Q test ( $\chi^2=1.9$ ;  $p=0.86$ ) and  $I^2$  test ( $I^2=0\%$ ) did not show a significant heterogeneity. The funnel plots identified all studies in the pseudo 95% CI (Figure 2B). The results did not differ when we performed a sensitivity analysis "leave-one-out."

### Effect of the type of wine consumed on PCa risk


Five studies investigated the risk of PCa according to consumption of white or red wine. We used RRs reported for moderate consumption (the same dose for white and red wine was considered). Four were cohort studies (222,447 subjects, from which 6,184 developed PCa during observation/follow-up)<sup>16,23,25,28</sup> and one was a case-control study.<sup>22</sup>

Clinical Epidemiology downloaded from https://www.dovepress.com/ by 104.200.47.132 on 18-Apr-2018 For personal use only.



**Figure 3** Forest plot for risk of PCa in the case of moderate consumption of wine (all studies).

**Abbreviations:** PCa, prostate cancer; pts, patients.



**Figure 4** Forest plot for risk of PCa in the case of moderate consumption of wine (cohort studies).

**Abbreviations:** PCa, prostate cancer; pts, patients.

The main characteristics of the included studies, as well as dose of wine consumption, are shown in Table 2 for white wine and in Table 3 for red wine. Moderate white wine consumption increased significantly the risk of PCa with a pooled RR of 1.26 (95% CI 1.10–1.43,  $p=0.001$ ) in the multivariable analysis (Figure 5). The Cochrane's Q test ( $\chi^2=4.6$ ;  $p=0.2$ ) and  $I^2$  test ( $I^2=34.4\%$ ) did not show a significant heterogeneity. The funnel plots identified all studies in the pseudo 95% CI (Figure 2C). When we excluded from the analysis the results reported by Sutcliffe et al,<sup>25</sup> moderate white wine consumption was not associated with an increased risk of PCa: pooled RR 1.05 (95% CI 0.87–1.28,  $p=0.56$ ). In all the other cases of exclusion, one study from the analysis showed that white wine was associated with an increased risk of Pca.

Moderate red wine consumption was associated with a decreased risk of PCa with a pooled RR of 0.88 (95% CI 0.78–0.999,  $p=0.047$ ) in the multivariable analysis (Figure 6). The Cochrane's Q test ( $\chi^2=2.16$ ;  $p=0.53$ ) and  $I^2$  test ( $I^2=0\%$ ) did not show a significant heterogeneity. The funnel plots identified all studies in the pseudo 95% CI (Figure 2D). The results remain significant also after the addition of the RRs from the case–control study of Schoonen et al<sup>22</sup> with a pooled RR of 0.86 (95% CI 0.76–0.97,  $p=0.01$ ). However, in this case the heterogeneity increased, but not to a significant level, Cochrane's Q test ( $\chi^2=6.06$ ;  $p=0.19$ ) and  $I^2$  test ( $I^2=34\%$ ). When we excluded from the analysis the results reported by Sutcliffe et al,<sup>25</sup> moderate red wine consumption was not associated with a decreased risk of PCa: pooled RR

**Table 2** Studies investigating the impact of white wine consumption on the risk of PCa


No.	Study	Year	Country	Study type	No. of pts	Age (years)	Variables	RRs white wine and risk of PCa	Dose	Follow-up (years)
1	Schuurman et al <sup>16</sup>	1999	the Netherlands	Case–cohort	58,279/ 680 Pca	55–69	Age, socioeconomic status, family history of Pca	1.0 (0.7–1.4)	0.1–4 g/day	6.3
2	Schoonen et al <sup>22</sup>	2005	King County, WA, USA	Case–control	703/ 753 Pca	40–64	Age, PSA screening, total lifetime number of female sexual partners, smoking status, and consumption of other types of alcohol	0.91 (0.44–1.86)	≥8 drinks/week	–
3	Velicer et al <sup>23</sup>	2006	Washington, USA	Case–cohort	34,565/ 816 Pca	50–76	Age, PSA, other types of alcohol consumed	1.12 (0.74–1.68)	5 drinks/week to <2/day	4
4	Sutcliffe et al <sup>25</sup>	2007	USA	Case–cohort	45,433/ 3,348 Pca	40–75	Age, race/ethnicity, BMI, cumulative family history of Pca, height, cigarette smoking in the past 10 years, baseline intakes of total energy, tomato sauce, red meat, fish, calcium and vitamin E, baseline energy-adjusted intakes of fructose and a-linolenic acid, physical activity and updated diabetes mellitus type 2 and vasectomy status, and all other specific alcoholic beverage types	1.42 (1.19–1.69)	2–4 drinks/week	16
5	Chao et al <sup>28</sup>	2010	California, USA	Case–cohort	84,170/ 1,340 Pca	45–69	Age, race/ethnicity, income, BMI, intake of other alcoholic beverage, meat consumption, family history of Pca, person history of PSA testing, STI, BPH, BPH surgery, prostatitis, and diabetes mellitus	1.10 (0.81–1.49)	>1 drink/day	5

**Abbreviations:** Pca, prostate cancer; pts, patients; RRs, risk ratios; BMI, body mass index; PSA, prostate-specific antigen; STIs, sexually transmitted infections; BPH, benign prostatic hyperplasia.


**Table 3** Studies investigating the impact of red wine consumption on the risk of PCa

No.	Study	Year	Country	Study type	No. of pts	Age (years)	Variables	RRs Red wine and risk of PCa	Dose	Follow-up (years)
1	Schuurman et al <sup>16</sup>	1999	the Netherlands	Case-cohort	58,279/680 PCa	55–69	Age, socioeconomic status, family history of PCa	1.0 (0.7–1.3)	0.1–4 g/day	6.3
2	Schoonen et al <sup>22</sup>	2005	King County, WA, USA	Case-control	703/753 PCa	40–64	Age, PSA screening, total lifetime number of female sexual partners, smoking status, and consumption of other types of alcohol	0.45 (0.23–0.85)	≥8 drinks/week	–
3	Velicer et al <sup>23</sup>	2006	Washington, USA	Case-cohort	34,565/816 PCa	50–76	Age, PSA, other types of alcohol consumed	0.98 (0.72–1.33)	5 drinks/week to <2/day	4
4	Sutcliffe et al <sup>25</sup>	2007	USA	Case-cohort	45,433/3,348 PCa	40–75	Age, race/ethnicity, BMI, cumulative family history of PCa, height, cigarette smoking in the past 10 years, baseline intakes of total energy, tomato sauce, red meat, fish, calcium and vitamin E, baseline energy-adjusted intakes of fructose and $\alpha$ -linolenic acid, physical activity and updated diabetes mellitus type 2 and vasectomy status, and all other specific alcoholic beverage types	0.79 (0.64–0.97)	2–4 drinks/week	16
5	Chao et al <sup>28</sup>	2010	California, USA	Case-cohort	84,170/1,340 PCa	45–69	Age, race/ethnicity, income, BMI, intake of other alcoholic beverage, meat consumption, family history of PCa, person history of PSA testing, STI, BPH, BPH surgery, prostatitis, and diabetes mellitus	0.88 (0.70–1.12)	>1 drink/day	5

**Abbreviations:** PCa, prostate cancer; pts, patients; RRs, risk ratios; BMI, body mass index; PSA, prostate specific antigen; BPH, benign prostatic hyperplasia; STIs, sexually transmitted infections.

**Figure 5** Forest plot for the risk of PCa in the case of moderate consumption of white wine (cohort studies).

**Abbreviations:** PCa, prostate cancer; pts, patients.



**Figure 6** Forest plot for risk of PCa in the case of moderate consumption of red wine (cohort studies).

**Abbreviations:** PCa, prostate cancer; pts, patients.

0.88 (95% CI 0.71–1.09,  $p=0.24$ ). In all the other cases of exclusion, only one study from the analysis showed that red wine was associated with a decreased risk of PCa.

## Discussion

This study is to our knowledge the first meta-analysis to investigate the impact of moderate wine consumption and the risk of developing PCa, including 611,169 subjects from 17 studies. According to this meta-analysis moderate wine consumption is not a risk factor for PCa development. Interestingly, the analysis regarding type of wine consumed sustains the fact that moderate wine consumption does not impact PCa risk. We found an antagonist effect as moderate white wine consumption increases the risk of PCa, whereas moderate red wine consumption had a protective role against PCa. However, when we excluded the results reported by Sutcliffe et al<sup>25</sup> (45,433 subjects with 16 years follow-up), there was not a significant association between type of wine consumed and risk of PCa.

Nevertheless, our meta-analysis has several limitations. First, there is a selection bias in the studies as all were nonrandomized observational or case–control studies. Second, the definition of moderate consumption is imprecise with differences between studies introducing heterogeneous results. Still, all studies had a maximum of one glass of wine per day as moderate consumption. Third, despite a large number of patients in our analyses, the number of studies in our meta-analysis was limited to 17. Fourth, most studies were done in western countries with a likely preponderance

of Caucasians. Metabolization and polymorphisms are highly variable between races and habits. Fifth, we decided to restrict the present meta-analysis to “moderate consumption” of wine alone, thus precluding analyses of dose–response relationship. We analyzed only the effect of moderate consumption; as in many countries, there are dietary habits that include one glass of wine per day during meals and the scope of the meta-analysis was not to encourage alcohol/wine consumption, but instead to point out the effects of responsible wine drinking on the risk of PCa.

The relationship between alcohol consumption and the risk of PCa remains a controversial issue.<sup>32</sup> Middleton Fillmore et al demonstrated in a meta-analysis that heavy alcohol consumption is associated with a higher risk of developing PCa.<sup>33</sup> Similarly, Zhao et al’s meta-analysis showed a significant dose–response relationship between level of alcohol intake and risk of PCa.<sup>9</sup> On the contrary, a large prospective European study that included 142,607 male participants found no association between alcohol consumption and PCa risk.<sup>10</sup> Regarding types of alcohol consumption, in a large cohort of 3,927 subjects, Demoury et al showed that beer was associated with a 37% increase risk of high-grade PCa.<sup>30</sup> In the present study, we found that wine is not associated with an increased risk of PCa as other alcohol or beer consumption is. This could be based on several factors that make wine less harmful than other types of alcohols. One of the factors might be the chemical composition of wine, which is a hydroalcoholic solution (~78% water) with a wide range of bioactive chemical components, including

aldehydes, esters, ketones, lipids, minerals, organic acids, phenolics, soluble proteins, sugars, and vitamins.<sup>34</sup> Second, the anticarcinogenic effect of polyphenols mainly contained by red wine may balance any other harmful effects of wine consumption.<sup>35</sup> Third, in the case of beer, the bioavailability of the phenolic compounds is very low, thus decreasing their potential anticarcinogenic effects.<sup>36</sup>

Furthermore, the mechanism between alcohol consumption and carcinogenesis is not fully understood. It seems to be based on acetaldehyde, the first metabolite of ethanol that has been suggested to be carcinogenic by promoting cancer development through various mechanisms, such as interference with DNA replication, induction of DNA damage, and formation of DNA adducts.<sup>37</sup> However, wine consumption, especially red wine, has been associated with decreased inflammation and overall mortality as well as moderate alcohol consumption.<sup>10,38</sup> Schoonen et al<sup>22</sup> and Sutcliffe et al<sup>25</sup> found, in large cohort studies, that red wine consumption decreases the risk of PCa, whereas white wine does not. Red wine's protective role against PCa development could be due to the bioactivity of polyphenols that are a complex mixture of flavonoids (such as anthocyanins and flavan-3-ols) and nonflavonoids (such as resveratrol, cinnamates, and gallic acid). Resveratrol is the most studied compound and its concentration is 10-fold higher than in white wine.<sup>39</sup> Resveratrol is added from the skin of red grapes during the creation process. Its concentration in red wine ranges from 1.2 to 2.0 g/L.<sup>39</sup> It has been studied regarding its anticarcinogenesis including PCa, and many studies showed that resveratrol causes cell growth, proliferation inhibition, and activation of apoptosis in human PCa cell lines including PC3, DU145, and LNCaP.<sup>40–43</sup> Sgambato et al found that resveratrol not only inhibits cell proliferation but also prevents the accumulation of reactive oxygen species production and oxidative DNA damage in cells exposed to oxidative agents.<sup>44</sup> On the other hand, white wine contains also a small amount of resveratrol, but despite an experimental study that showed an association between white wine and antiproliferative effect, clinical studies do not support this finding.<sup>43</sup> Nevertheless, the beneficial effects of moderate red wine consumption might be due to all its compounds and not only due to resveratrol.<sup>39</sup> Although we focused only on “moderate” consumption of red wine in this study, it is unclear whether effectiveness of red wine polyphenols depends on the amount of consumption or not. To better assess the relationship between wine consumption, especially the appropriate amount of red wine and PCa risk in the general population, further studies are needed.

## Conclusion

In this meta-analysis, moderate wine consumption did not influence the risk of PCa. However, moderate consumption of white wine increased the risk of PCa, whereas moderate consumption of red wine had a protective role. This hypothesis-generating data should serve as a rationale for uncovering the molecular underpinnings of this differential effect in order to potentially devise prevention strategies in the at-risk population.

## Acknowledgments

MDV had an EUSP (European Urological Scholarship Programme) lab/clinical fellowship awarded by EAU (European Association of Urology) and an Ernst Mach Grant awarded by OeAD, Austria.

## Author Contributions

All authors contributed towards data analysis, drafting and critically revising the paper and agree to be accountable for all aspects of the work.

## Disclosure

The authors report no conflicts of interest in this work.

## References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. *CA Cancer J Clin.* 2017;67(1):7–30.
2. Center MM, Jemal A, Lortet-Tieulent J, et al. International variation in prostate cancer incidence and mortality rates. *Eur Urol.* 2012;61(6):1079–1092.
3. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer.* 2015;136(5):E359–E386.
4. Lynch HT, Kosoko-Lasaki O, Leslie SW, et al. Screening for familial and hereditary prostate cancer. *Int J Cancer.* 2016;138(11):2579–2591.
5. Randazzo M, Müller A, Carlsson S, et al. A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau). *BJU Int.* 2016;117(4):576–583.
6. Eeles RA, Olama AAA, Benlloch S, et al. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. *Nat Genet.* 2013;45(4):385–391, 391e1–e2.
7. Tan DSW, Mok TSK, Rebbeck TR. Cancer genomics: diversity and disparity across ethnicity and geography. *J Clin Oncol.* 2016;34(1):91–101.
8. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. *Eur Urol.* 2017;71(4):618–629.
9. Zhao J, Stockwell T, Roemer A, Chikritzhs T. Is alcohol consumption a risk factor for prostate cancer? A systematic review and meta-analysis. *BMC Cancer.* 2016;16(1):845.
10. Rohrmann S, Linseisen J, Key TJ, et al. Alcohol consumption and the risk for prostate cancer in the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiol Biomark Prev.* 2008;17(5):1282–1287.

11. Aziz MH, Kumar R, Ahmad N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). *Int J Oncol*. 2003;23(1):17–28.
12. Jasiński M, Jasińska L, Ogrodowczyk M. Resveratrol in prostate diseases: a short review. *Cent Eur J Urol*. 2013;66(2):144–149.
13. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg*. 2010;8(5):336–341.
14. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomised studies in meta-analyses. Available from: [http://www.Ohri.ca/Programs/Clinical\\_epidemiology/Oxford.Htm](http://www.Ohri.ca/Programs/Clinical_epidemiology/Oxford.Htm). Accessed October 30, 2017.
15. Jain MG, Hislop GT, Howe GR, Burch JD, Ghadirian P. Alcohol and other beverage use and prostate cancer risk among Canadian men. *Int J Cancer*. 1998;78(6):707–711.
16. Schuurman AG, Goldbohm RA, van den Brandt PA. A prospective cohort study on consumption of alcoholic beverages in relation to prostate cancer incidence (The Netherlands). *Cancer Causes Control*. 1999;10(6):597–605.
17. Sesso HD, Paffenbarger RS, Lee IM. Alcohol consumption and risk of prostate cancer: The Harvard Alumni Health Study. *Int J Epidemiol*. 2001;30(4):749–755.
18. Albertsen K, Grønbaek M. Does amount or type of alcohol influence the risk of prostate cancer? *Prostate*. 2002;52(4):297–304.
19. Crispo A, Talamini R, Gallus S, et al. Alcohol and the risk of prostate cancer and benign prostatic hyperplasia. *Urology*. 2004;64(4):717–722.
20. Platz EA, Leitzmann MF, Rimm EB, Willett WC, Giovannucci E. Alcohol intake, drinking patterns, and risk of prostate cancer in a large prospective cohort study. *Am J Epidemiol*. 2004;159(5):444–453.
21. Chang ET, Hedelin M, Adami H-O, Grönberg H, Bälter KA. Alcohol drinking and risk of localized versus advanced and sporadic versus familial prostate cancer in Sweden. *Cancer Causes Control*. 2005;16(3):275–284.
22. Schoonen WM, Salinas CA, Kiemeny LALM, Stanford JL. Alcohol consumption and risk of prostate cancer in middle-aged men. *Int J Cancer*. 2005;113(1):133–140.
23. Velicer CM, Kristal A, White E. Alcohol use and the risk of prostate cancer: results from the VITAL cohort study. *Nutr Cancer*. 2006;56(1):50–56.
24. Baglietto L, Severi G, English DR, Hopper JL, Giles GG. Alcohol consumption and prostate cancer risk: results from the Melbourne collaborative cohort study. *Int J Cancer*. 2006;119(6):1501–1504.
25. Sutcliffe S, Giovannucci E, Leitzmann MF, et al. A prospective cohort study of red wine consumption and risk of prostate cancer. *Int J Cancer*. 2007;120(7):1529–1535.
26. Benedetti A, Parent M-E, Siemiatycki J. Lifetime consumption of alcoholic beverages and risk of 13 types of cancer in men: results from a case-control study in Montreal. *Cancer Detect Prev*. 2009;32(5–6):352–362.
27. Watters JL, Park Y, Hollenbeck A, Schatzkin A, Albanes D. Alcoholic beverages and prostate cancer in a prospective US cohort study. *Am J Epidemiol*. 2010;172(7):773–780.
28. Chao C, Haque R, Van Den Eeden SK, Caan BJ, Poon K-YT, Quinn VP. Red wine consumption and risk of prostate cancer: the California Men's Health Study. *Int J Cancer*. 2010;126(1):171–179.
29. McGregor SE, Courneya KS, Kopciuk KA, Tosevski C, Friedenreich CM. Case-control study of lifetime alcohol intake and prostate cancer risk. *Cancer Causes Control*. 2013;24(3):451–461.
30. Demoury C, Karakiewicz P, Parent M-E. Association between lifetime alcohol consumption and prostate cancer risk: a case-control study in Montreal, Canada. *Cancer Epidemiol*. 2016;45:11–17.
31. Papa NP, MacInnis RJ, Jayasekara H, et al. Total and beverage-specific alcohol intake and the risk of aggressive prostate cancer: a case-control study. *Prostate Cancer Prostatic Dis*. 2017;20(3):305–310.
32. Fowke JH, Howard L, Andriole GL, Freedland SJ. Alcohol intake increases high-grade prostate cancer risk among men taking dutasteride in the REDUCE trial. *Eur Urol*. 2014;66(6):1133–1138.
33. Middleton Fillmore K, Chikritzhs T, Stockwell T, Bostrom A, Pascal R. Alcohol use and prostate cancer: a meta-analysis. *Mol Nutr Food Res*. 2009;53(2):240–255.
34. Fernandes I, Pérez-Gregorio R, Soares S, Mateus N, de Freitas V. Wine flavonoids in health and disease prevention. *Molecules*. 2017;22(2):pii, E292.
35. Sancho M, Mach N. [Effects of wine polyphenols on cancer prevention]. *Nutr Hosp*. 2014;31(2):535–551. Spanish.
36. Grønbaek M, Mortensen EL, Mygind K, et al. Beer, wine, spirits and subjective health. *J Epidemiol Community Health*. 1999;53(11):721–724.
37. Seitz HK, Becker P. Alcohol metabolism and cancer risk. *Alcohol Res Health J*. 2007;30(1):38–41, 44–47.
38. Holman CD, English DR, Milne E, Winter MG. Meta-analysis of alcohol and all-cause mortality: a validation of NHMRC recommendations. *Med J Aust*. 1996;164(3):141–145.
39. Arranz S, Chiva-Blanch G, Valderas-Martínez P, Medina-Remón A, Lamuela-Raventós RM, Estruch R. Wine, beer, alcohol and polyphenols on cardiovascular disease and cancer. *Nutrients*. 2012;4(7):759–781.
40. Kampa M, Hatzoglou A, Notas G, et al. Wine antioxidant polyphenols inhibit the proliferation of human prostate cancer cell lines. *Nutr Cancer*. 2000;37(2):223–233.
41. Brizuela L, Dayon A, Doumerc N, et al. The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer. *FASEB J*. 2010;24(10):3882–3894.
42. Burton LJ, Rivera M, Hawsawi O, et al. Muscadine grape skin extract induces an unfolded protein response-mediated autophagy in prostate cancer cells: a TMT-based quantitative proteomic analysis. *PLoS One*. 2016;11(10):e016411.
43. Tenta R, Fragopoulou E, Tsoukala M, et al. Antiproliferative effects of red and white wine extracts in PC-3 prostate cancer cells. *Nutr Cancer*. 2017;69(6):952–961.
44. Sgambato A, Ardito R, Faraglia B, Boninsegna A, Wolf FI, Cittadini A. Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. *Mutat Res*. 2001;496(1–2):171–180.

## Supplementary materials

Study and year	Selection	Comparability	Exposure
Jain et al, 1998 <sup>1</sup>	★ ★ ★	★ ★	★ ★
Schuurman et al, 1999 <sup>2</sup>	★ ★	★ ★	★ ★
Sesso et al, 2001 <sup>3</sup>	★ ★ ★	★ ★	★ ★
Albertsen and Grønbaek, 2002 <sup>4</sup>	★ ★	★ ★	★ ★
Crispo et al, 2004 <sup>5</sup>	★ ★	★ ★	★ ★ ★
Platz et al, 2004 <sup>6</sup>	★ ★	★ ★	★ ★
Chang et al, 2005 <sup>7</sup>	★ ★ ★	★ ★	★ ★
Schoonen et al, 2005 <sup>8</sup>	★ ★ ★	★ ★	★ ★ ★
Baglietto et al, 2006 <sup>9</sup>	★ ★	★	★ ★ ★
Benedetti et al, 2009 <sup>10</sup>	★ ★ ★	★ ★	★ ★
Watters et al, 2010 <sup>11</sup>	★ ★ ★	★ ★	★ ★
McGregor et.al, 2013 <sup>12</sup>	★ ★ ★	★ ★	★ ★
Demoury et al, 2016 <sup>13</sup>	★ ★	★ ★	★ ★
Papa et al, 2017 <sup>14</sup>	★ ★	★ ★	★ ★
Velicer et al, 2006 <sup>15</sup>	★ ★ ★	★ ★	★ ★
Sutcliffe et al, 2007 <sup>16</sup>	★ ★	★ ★	★ ★
Chao et al, 2010 <sup>17</sup>	★ ★ ★	★ ★	★ ★

**Figure S1** Newcastle-Ottawa Scale.

**Notes:** Each study was judged on eight items, categorized into three groups: the selection of the study groups; the comparability of the groups; and the ascertainment of the exposure of interest for cohort studies. There was a maximum of 4 stars for the selection, 2 stars for the comparability, and 3 stars for exposure components. The highest quality studies are awarded up to 9 stars.

A

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants (performance bias)	Blinding of outcome (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	NOS	Adjusted for age	Adjusted for positive family history of PCa	Adjusted for benign prostatic hypertrophy	Adjusted for smoking status	Adjusted for socioeconomic status	Adjusted for body mass index
Study and year	Assessment of the main biases							Analysis of PCa risk					
Jain et al, 1998 <sup>1</sup>	Red	Red	Red	Red	Red	Red	7	Red	Green	Green	Red	Red	Red
Schuurman et al, 1999 <sup>2</sup>	Red	Red	Red	Red	Red	Red	6	Red	Green	Red	Red	Green	Red
Sesso et al, 2001 <sup>3</sup>	Red	Red	Red	Red	Red	Red	7	Red	Green	Red	Red	Red	Green
Albertsen and Grønbaek, 2002 <sup>4</sup>	Red	Red	Red	Red	Red	Red	6	Red	Green	Red	Red	Red	Green
Crispo et al, 2004 <sup>5</sup>	Red	Red	Red	Red	Red	Red	7	Red	Green	Red	Red	Red	Green
Platz et al, 2004 <sup>6</sup>	Red	Red	Red	Red	Red	Red	6	Red	Green	Red	Red	Red	Green
Chang et al, 2005 <sup>7</sup>	Red	Red	Red	Red	Red	Red	7	Red	Green	Red	Red	Red	Green
Schoonen et al, 2005 <sup>8</sup>	Red	Red	Red	Red	Red	Red	8	Red	Green	Red	Red	Red	Red
Baglietto et al, 2006 <sup>9</sup>	Red	Red	Red	Red	Red	Red	6	Red	Green	Red	Red	Red	Red
Benedetti et al, 2009 <sup>10</sup>	Red	Red	Red	Red	Red	Red	7	Red	Green	Red	Red	Red	Red
Watters et al, 2010 <sup>11</sup>	Red	Red	Red	Red	Red	Red	8	Red	Green	Red	Red	Red	Red
McGregor et al, 2013 <sup>12</sup>	Red	Red	Red	Red	Red	Red	7	Red	Green	Red	Red	Red	Red
Demoury et al, 2016 <sup>13</sup>	Red	Red	Red	Red	Red	Red	6	Red	Green	Red	Red	Red	Red
Papa et al, 2017 <sup>14</sup>	Red	Red	Red	Red	Red	Red	6	Red	Green	Red	Red	Red	Red

B

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants (performance bias)	Blinding of outcome (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	NOS	Adjusted for age	Adjusted for positive family history of PCa	Adjusted for benign prostatic hypertrophy	Adjusted for smoking status	Adjusted for socioeconomic status	Adjusted for body mass index
Study and year	Assessment of the main biases							Analysis of PCa risk					
Schuurman et al, 1999 <sup>2</sup>	Red	Red	Red	Red	Red	Red	6	Red	Green	Red	Red	Green	Red
Schoonen et al, 2005 <sup>9</sup>	Red	Red	Red	Red	Red	Red	8	Red	Green	Red	Red	Red	Red
Velicer et al, 2006 <sup>15</sup>	Red	Red	Red	Red	Red	Red	7	Red	Green	Red	Red	Red	Red
Sutcliffe et al, 2007 <sup>16</sup>	Red	Red	Red	Red	Red	Red	6	Red	Green	Red	Red	Red	Red
Chao et al, 2010 <sup>17</sup>	Red	Red	Red	Red	Red	Red	7	Red	Green	Red	Red	Red	Red

**Figure S2 (A)** Risk of bias summary of the studies that analyses the association between moderate wine consumption and PCa risk (red: high risk; green: low risk). **(B)** Risk of bias summary of the studies that analyses the association between moderate white and red wine consumption and PCa risk (red: high risk; green: low risk).

**Abbreviation:** NOS, Newcastle-Ottawa Scale.

## References

- Jain MG, Hislop GT, Howe GR, Burch JD, Ghadirian P. Alcohol and other beverage use and prostate cancer risk among Canadian men. *Int J Cancer*. 1998;78(6):707–711.
- Schuurman AG, Goldbohm RA, van den Brandt PA. A prospective cohort study on consumption of alcoholic beverages in relation to prostate cancer incidence (The Netherlands). *Cancer Causes Control CCC*. 1999;10(6):597–605.
- Sesso HD, Paffenbarger RS, Lee IM. Alcohol consumption and risk of prostate cancer: The Harvard Alumni Health Study. *Int J Epidemiol*. 2001;30(4):749–755.
- Albertsen K, Grønbaek M. Does amount or type of alcohol influence the risk of prostate cancer? *Prostate*. 2002;52(4):297–304.
- Crispo A, Talamini R, Gallus S, et al. Alcohol and the risk of prostate cancer and benign prostatic hyperplasia. *Urology*. 2004;64(4):717–722.
- Platz EA, Leitzmann MF, Rimm EB, Willett WC, Giovannucci E. Alcohol intake, drinking patterns, and risk of prostate cancer in a large prospective cohort study. *Am J Epidemiol*. 2004;159(5):444–453.
- Chang ET, Hedelin M, Adami H-O, Grönberg H, Bälter KA. Alcohol drinking and risk of localized versus advanced and sporadic versus familial prostate cancer in Sweden. *Cancer Causes Control*. 2005;16(3):275–284.
- Schoonen WM, Salinas CA, Kiemeny LALM, Stanford JL. Alcohol consumption and risk of prostate cancer in middle-aged men. *Int J Cancer*. 2005;113(1):133–140.
- Baglietto L, Severi G, English DR, Hopper JL, Giles GG. Alcohol consumption and prostate cancer risk: results from the Melbourne collaborative cohort study. *Int J Cancer*. 2006;119(6):1501–1504.
- Benedetti A, Parent M-E, Siemiatycki J. Lifetime consumption of alcoholic beverages and risk of 13 types of cancer in men: results from a case-control study in Montreal. *Cancer Detect Prev*. 2009;32(5–6):352–362.
- Watters JL, Park Y, Hollenbeck A, Schatzkin A, Albanes D. Alcoholic beverages and prostate cancer in a prospective US cohort study. *Am J Epidemiol*. 2010;172(7):773–780.
- McGregor SE, Courneya KS, Kopciuk KA, Tosevski C, Friedenreich CM. Case-control study of lifetime alcohol intake and prostate cancer risk. *Cancer Causes Control*. 2013;24(3):451–461.
- Demoury C, Karakiewicz P, Parent M-E. Association between lifetime alcohol consumption and prostate cancer risk: a case-control study in Montreal, Canada. *Cancer Epidemiol*. 2016;45:11–17.
- Papa NP, MacInnis RJ, Jayasekara H, et al. Total and beverage-specific alcohol intake and the risk of aggressive prostate cancer: a case-control study. *Prostate Cancer Prostatic Dis*. 2017;20(3):305–310.
- Velicer CM, Kristal A, White E. Alcohol use and the risk of prostate cancer: results from the VITAL cohort study. *Nutr Cancer*. 2006;56(1):50–56.
- Sutcliffe S, Giovannucci E, Leitzmann MF, et al. A prospective cohort study of red wine consumption and risk of prostate cancer. *Int J Cancer*. 2007;120(7):1529–1535.
- Chao C, Haque R, Van Den Eeden SK, Caan BJ, Poon K-YT, Quinn VP. Red wine consumption and risk of prostate cancer: the California Men's Health Study. *Int J Cancer*. 2010;126(1):171–179.

### Clinical Epidemiology

#### Publish your work in this journal

Clinical Epidemiology is an international, peer-reviewed, open access, online journal focusing on disease and drug epidemiology, identification of risk factors and screening procedures to develop optimal preventative initiatives and programs. Specific topics include: diagnosis, prognosis, treatment, screening, prevention, risk factor modification,

Submit your manuscript here: <https://www.dovepress.com/clinical-epidemiology-journal>

systematic reviews, risk and safety of medical interventions, epidemiology and biostatistical methods, and evaluation of guidelines, translational medicine, health policies and economic evaluations. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use.

Dovepress